Stay updated on Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page
- Check3 days agoChange DetectedThe page footer now shows an updated release/revision version (from v3.5.2 to v3.5.3) for the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check10 days agoChange DetectedRevision: v3.5.2 is now shown on the page, replacing the previous Revision: v3.5.0.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedRevision label updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.0%

- Check46 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3; no study details or navigation were affected.SummaryDifference0.0%

- Check75 days agoChange DetectedAdded Revision: v3.4.2 and removed the funding-lapse notice (and its prior Revision: v3.4.1). No core study content, eligibility criteria, or results were modified.SummaryDifference0.3%

- Check82 days agoChange DetectedAdded a government funding notice detailing operational status of the NIH Clinical Center and updated the site to revision v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib Combo with PD-(L)1 in Urothelial Carcinoma Clinical Trial page.